Piramal Pharma shares surge 14% as Q2 profitability improves, FY27 outlook raised

What happened

Piramal Pharma shares jumped 14% on Wednesday, October 28, after the company reported second-quarter net profit of ₹5.58 crore versus a ₹99.2 crore loss a year earlier, with revenue up 28% and an improved FY27 outlook.

Confirmed

Global impact / market context

A swing from loss to profit, plus margins expanding to 13.3% from 7.8%, suggests higher factory use is spreading fixed costs over more sales. If sustained, that supports more internally funded capital spending and steadier earnings for the pharmaceutical company.

Analyst inference

All three business verticals grew, with the contract manufacturing arm up 36%, hospital generics up 32% and consumer healthcare up 13%. The scale of the share move implies investors had expected weaker results, so positioning likely shifted toward the stock on the day.

Analyst inference

What to watch

1. The company raised its revenue growth outlook for FY27, so watch whether later quarterly revenue actually meets that higher guidance, since any shortfall could reverse the share gain. Confirmed
2. Watch whether margin gains persist as capacity utilisation rises, which means factories running closer to full use; if operating leverage fades, profit per sale could slip back toward earlier levels. Proposed
3. Watch customer additions and audits, 22 and 110 respectively in the first half, as a signal of future contract manufacturing revenue, because new clients typically convert to sales over later quarters. Analyst inference

Evidence

• Original source link unavailable